Evidence map›Paper›PMID 41721535›Full record

ArticleBritish journal of haematology2026

Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.

Silvio Ligia, Giovanni Manfredi Assanto, Tania Soriano, Luca Vincenzo Cappelli, Mauro Passucci, Giorgia Annechini, Gianna Maria D'Elia, Alessandro Pulsoni, Maurizio Martelli, Ilaria Del Giudice

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Silvio LigiaHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-2803-3766
Giovanni Manfredi AssantoHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-6190-9635
Tania SorianoHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Luca Vincenzo CappelliHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-8090-3880
Mauro PassucciHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-1872-2218
Giorgia AnnechiniHematology, AOU Policlinico Umberto I, Rome, Italy.
Gianna Maria D'EliaHematology, AOU Policlinico Umberto I, Rome, Italy.
Alessandro PulsoniHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-7429-8004
Maurizio MartelliHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Ilaria Del GiudiceHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-6864-9533

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Older patients with classic Hodgkin lymphoma experience poorer outcomes than younger individuals, due to comorbidities and functional limitations affecting treatment tolerance. In this retrospective single-centre study of 140 patients, we evaluated treatment patterns, outcomes and the prognostic value of two geriatric scores: the Age, Comorbidities and Albumin (ACA) Index and the Frailty Score. Most patients (87.9%) received standard ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)/AVD (doxorubicin, vinblastine and dacarbazine) regimens. At median follow-up (65 months), 5-year progression-free survival (PFS) and overall survival (OS) were 65% and 78.5%, respectively; treatment-related mortality was 7.8%. First-line therapy (AVD-based versus other) significantly influenced PFS (61.8% vs. 23.5%, p = 0.002) and OS (69.1% vs. 35.3%, p = 0.001). ACA Index stratified patients into four risk categories with progressively lower 5-year OS (92%-64.3%, p = 0.003). According to Frailty Score, 37.9% were fit, 54.3% unfit and 7.8% frail, with corresponding 5-year OS of 79.2%, 59.2% and 36.4% (p < 0.0001). Multivariate analysis identified age ≥80 years, extra-nodal involvement and advanced stage according to German Hodgkin Study Group (GHSG) classification as independent predictors of PFS; age ≥80 years, advanced stage (GHSG) and Frailty Score independently predicted OS. Our findings confirm that standard therapies achieve favourable outcomes in older patients, but chronological age alone is insufficient for treatment decisions. The Frailty Score offers an accessible prognostic tool to guide therapy, supporting the integration of geriatric assessment into treatment planning for this underrepresented population.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsGeriatric AssessmentHodgkin DiseaseAgedAged, 80 and overAge FactorsBleomycinDacarbazineDoxorubicinFemaleHumansMalePrognosisRetrospective StudiesVinblastineBleomycinDacarbazineDoxorubicinVinblastineACA indexFrailty Scoregeriatric assessmentHodgkin lymphomaolder patients

Identifiers

PMID41721535
PMCPMC13071466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.